November 21, 2022
5 min watch
Tantravahi reports consulting and serving on advisory boards for AbbVie, Karyopharm Therapeutics and Novartis; and providing clinical research support for Karyopharm Therapeutics.
In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy.
The data was reviewed at the 14th International Congress on Myeloproliferative Neoplasms.
“These patients that are treated with this investigational agent have completely became [sic] phlebotomy-independent with control of the hemoglobin hematocrit,” Tantravahi, hematologist with University of Utah Health and Huntsman Cancer Institute, said.
However, he mentioned that the agent does not decrease white blood cell or platelet count, so the effect on risk for cardiovascular events “has yet to be determined.”
Tantravahi also discussed “emerging data” surrounding ropeginterferon in the setting of polycythemia vera.
“The treatment with interferon has reemerged in treatment of [polycythemia vera] because of the notion that this drug has selective effect on JAK2-mutated cells in polycythemia vera,” he said.
- Ginzburg Y. Hepcidin mimetics in polycythemia vera. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.
- Gisslinger H. Ropeginterferon: first- and second-line therapy in PV. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.